Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio para evaluar la eficacia y seguridad de obinutuzumab en participantes con lupus eritematoso sistémico (ALLEGORY)

10 de noviembre de 2026 actualizado por: Hoffmann-La Roche

Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico para evaluar la eficacia y seguridad de obinutuzumab en pacientes con lupus eritematoso sistémico

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

303

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Buenos Aires, Argentina, C1015ABO
        • Organizacion Medica de Investigacion
      • Buenos Aires, Argentina, C1111AAJ
        • DOM Centro de Reumatología
      • San Miguel, Argentina, T4000AXL
        • Centro de Investigaciones Médicas Tucuman
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil, 40150-150
        • Ser Servicos Especializados Em Reumatologia
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasil, 30130-100
        • Hospital das Clinicas - UFMG
      • Belo Horizonte, Minas Gerais, Brasil, 30150-221
        • Santa Casa de Misericordia
      • Juiz de Fora, Minas Gerais, Brasil, 36010-570
        • Centro Mineiro de Pesquisa - CMIP
    • Paraná
      • Curtiba, Paraná, Brasil, 80030-110
        • Centro de Estudos em Terapias Inovadoras ? CETI
    • São Paulo
      • Ribeirão Preto, São Paulo, Brasil, 14051-140
        • Hospital das Clinicas - FMUSP Ribeirao Preto
      • São Bernardo do Campo, São Paulo, Brasil, 09715-090
        • Centro Multidisciplinar de Estudos Clínicos - CEMEC*X*
      • Prague, Chequia, 128 50
        • Revmatologicky Ustav
      • Barcelona, España, 08035
        • Hospital Universitario Vall d'Hebron
      • Madrid, España, 28007
        • Hospital General Universitario Gregorio Marañon
    • Alabama
      • Anniston, Alabama, Estados Unidos, 36207
        • Pinnacle Research Group
    • Arkansas
      • Searcy, Arkansas, Estados Unidos, 72143
        • Unity Health - White County Medical Center- Rheumatology
    • California
      • Fullerton, California, Estados Unidos, 92835
        • Providence Medical Foundation
    • Florida
      • Aventura, Florida, Estados Unidos, 33180
        • Arthritis & Rheumatism
    • Michigan
      • Lansing, Michigan, Estados Unidos, 48911
        • Great Lakes Center of Rheumatology
      • Troy, Michigan, Estados Unidos, 48047
        • Clinical Research Institute of Michigan, LLC
    • New York
      • Great Neck, New York, Estados Unidos, 11021
        • Northwell Health Division of Rheumatology
      • New York, New York, Estados Unidos, 10032
        • Columbia University Medical Center
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204
        • Joint & Muscle Research Institute
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43212
        • The Ohio State University Wexner Medical Center
      • Middleburg Heights, Ohio, Estados Unidos, 44130
        • Paramount Medical Research & Consulting, LLC
    • Texas
      • Colleyville, Texas, Estados Unidos, 76034
        • Precision Comprehensive Clinical Research Solutions
      • El Paso, Texas, Estados Unidos, 79902
        • Texas Arthritis Center
      • Houston, Texas, Estados Unidos, 77054
        • Prolato Clinical Research Center
      • Paris, Francia, 75651
        • Ch Pitie Salpetriere
    • Lazio
      • Rome, Lazio, Italia, 00168
        • Policlinico Universitario Agostino Gemelli
    • Lombardy
      • Milan, Lombardy, Italia, 20132
        • IRCCS S. Raffaele
    • Tuscany
      • Pisa, Tuscany, Italia, 56126
        • A.O. Universitaria Pisana
    • Veneto
      • Cona (Ferrara), Veneto, Italia, 44124
        • Azienda Ospedaliero-Universitaria Di Ferrara Arcispedale Santanna
      • Padova, Veneto, Italia, 35128
        • Uni Di Padova
    • Coahuila
      • Torreón, Coahuila, México, 27000
        • Centro de Investigacion Alberto Bazzoni S.A. de C.V.
    • Estado de Baja California
      • Mexicali, Estado de Baja California, México, 21100
        • Unidad de Reumatologia Rehabilitacion Integral
    • Mexico CITY (federal District)
      • Mexico City, Mexico CITY (federal District), México, 11850
        • Centro de Investigación y Tratamiento Reumatológico S.C.
    • Nuevo León
      • Monterrey, Nuevo León, México, 64460
        • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
      • Auckland, Nueva Zelanda, 2025
        • Middlemore Hospital
      • Wellington, Nueva Zelanda, 0621
        • Wellington Hospital
      • Arequipa, Perú, 04000
        • Hogar Clínica San Juan de Dios
      • Lima, Perú
        • Instituto de Ginecología y Reproducción
      • Lima, Perú, 15431
        • Clínica San Juan Bautista CSJB
      • San Isidro, Perú, L27 Lima
        • Clinica El Golf
      • Trujillo, Perú, 13008
        • Clinica San Antonio;Investigaciones Trujillo S.A.C.
      • Bydgoszcz, Polonia, 85-168
        • Szpital Uniwersytecki
      • Poznan, Polonia, 61-397
        • Prywatna Praktyka Lekarska
      • Poznan, Polonia, 61-545
        • Ortopedyczno Rehab Szpital Klinic im Wiktora Degi UM
      • Poznan, Polonia, 60-218
        • Medyczne Centrum Hetmanska
      • Warsaw, Polonia, 02-118
        • Rheuma Medicus Zaklad Opieki Zdrowotnej
      • Warsaw, Polonia, 00-874
        • MICS Centrum Medyczne Warszawa
      • Wroc?aw, Polonia, 52-210
        • REUMATOP Grzegorz Rozumek, Karin Pistorius Spó?ka Jawna
      • Cambridge, Reino Unido, CB2 2QQ
        • Addenbrooke'S Hospital
      • Leeds, Reino Unido, LS1 3EX
        • Chapel Allerton Hospital
      • London, Reino Unido, SE1 9RT
        • Guy's Hospital
      • London, Reino Unido, NW3 2QG
        • Royal Free Hospital
      • Manchester, Reino Unido, M13 9WL
        • Manchester Royal Infirmary
    • Bashkortostan Republic
      • Ufa, Bashkortostan Republic, Rusia, 450005
        • Republican clinical hospital named after G.G. Kuvatov
    • Moscow Oblast
      • Moscow, Moscow Oblast, Rusia, 115522
        • Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, Rusia, 197341
        • FGBU ?Federal Medical and Research Center named after V.A.Almazov? Russian Ministry of Health
      • Cape Town, Sudáfrica, 7500
        • Panorama Medical Center
      • Pretoria, Sudáfrica, 0002
        • Emmed Research
      • Somerset West, Sudáfrica, 7130
        • Clinical Trials Network Helderberg
      • Umhlanga, Sudáfrica, 4319
        • Dr Asokan Naidoo

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria >=12 weeks prior to screening
  • Anti-nuclear antibody (ANA) >=1:80, or anti-dsDNA and/or anti-Sm antibodies above the upper limit of normal (ULN), as determined by the central laboratory at screening
  • Low C3 or low C4 or low CH50 complement as determined by the central laboratory at screening
  • High disease activity at screening, based on; BILAG-2004 (Category A disease in >=1 organ system and/or Category B disease in >=2 organ systems), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) (score >=8) and Physician's Global Assessment (PGA) (score >=1.0 on a 0 to 3 visual analogue scale [VAS])
  • High disease activity on Day 1, based on; SLEDAI-2K (score >=8) and PGA (score >=1.0 on a 0 to 3 VAS)
  • Current receipt of >=1 of the following classes of standard therapies for the treatment of SLE at stable doses: oral corticosteroid (OCS), antimalarials, conventional immunosuppressants
  • Other inclusion criteria may apply
  • The Medical Monitor may be consulted if there are any questions related to eligibility criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Presence of significant lupus-associated renal disease and/or renal impairment
  • Receipt of an excluded therapy, including any anti-CD20, anti-CD19 therapy less than 9 months prior to screening or during screening; or cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
  • Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude patient participation
  • Known active infection of any kind or recent major episode of infection
  • Intolerance or contraindication to study therapies
  • Other exclusion criteria may apply

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Obinutuzumab

Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1 and at Weeks 2, 24 and 26.

Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.

Otros nombres:
  • Gazyva, GA101, RO5072759

Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.

Diphenhydramine 50 mg will be administered as premedication prior to infusions.

Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.

Comparador de placebos: Placebo

Placebo participants will receive obinutuzumab matched placebo on Day 1 and at Weeks 2, 24 and 26.

Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.

Diphenhydramine 50 mg will be administered as premedication prior to infusions.

Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.

Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants Who Achieved SLE Responder Index (SRI4) at Week 52
Periodo de tiempo: At Week 52

Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); 2) No new systems or organs affected, as defined by >=1 new British Isles Lupus Assessment Group (BILAG) A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point Physician's Global Assessment-Visual Analog Scale (PGA-VAS). SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 52

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants Who Achieved British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) at Week 52
Periodo de tiempo: At Week 52

Achieving BICLA was defined as all of the following: 1) Reduction of all baseline BILAG-2004 A items to B/C/D and baseline BILAG-2004 B items to C/D; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No net increase in SLEDAI-2K score from baseline; 4) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 52
Percentage of Participants Who Achieved Sustained Oral Corticosteroid Control (OCS) (<=7.5 mg/Day) From Week 40 Through Week 52
Periodo de tiempo: From Week 40 through Week 52

Sustained OCS was defined as all of the following: 1) No treatment with prednisone >7.5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders.

From Week 40 through Week 52
Percentage of Participants Who Achieved Sustained SRI(4) Response From Week 40 Through Week 52
Periodo de tiempo: From Week 40 Through Week 52

Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

From Week 40 Through Week 52
Percentage of Participants With SRI(6) Response at Week 52
Periodo de tiempo: At Week 52

Achieving SRI(6) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 52
Time to BILAG Flare Over 52 Weeks
Periodo de tiempo: At Week 52

BILAG flare was defined as the occurrence of >=1 new BILAG A or >=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and lack of efficacy (regardless of discontinuation from treatment or study) were considered as having a flare at the time of the event. Participants who experienced early discontinuation from the blinded period due to reasons other than lack of efficacy and those who completed 52 week treatment period without flare were censored at the time of the event. Kaplan-Meier (KM) method was used to estimate the time to first BILAG flare.

At Week 52
Percentage of Participants Who Achieved SRI(4) at Week 24
Periodo de tiempo: At Week 24

Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 24
Percentage of Participants Who Achieved Clinical SRI(4) at Week 52
Periodo de tiempo: At Week 52

Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K, excluding points from the immunologic components (low complement and elevated anti-dsDNA antibody; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 52
Percentage of Participants Who Achieved SRI(4) at Week 52 on Low-dose of Corticosteroids
Periodo de tiempo: At Week 52

Achieving SRI(4) on low doses of corticosteroids was defined as all of the following: 1) Reduction from baseline of >=4 points in SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS; 4) Prednisone <=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 52
Percentage of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) at Week 52
Periodo de tiempo: At Week 52

LLDAS response was defined as achievement of all of the following: 1) SLEDAI-2K <=4; 2) No SLEDAI-2K activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no BILAG hemolytic anemia or gastrointestinal activity; 3) No new SLEDAI-2K activity compared with the previous assessment PGA-VAS <=1; 4) Current prednisone dose <=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).

At Week 52
Percentage of Participants Who Achieved Definition of Remission in SLE (DORIS) at Week 52
Periodo de tiempo: At Week 52

DORIS response was defined as achievement of all of the following: 1) Clinical SLEDAI-2K (cSLEDAI-2K) = 0, where cSLEDAI-2K is defined as total SLEDAI-2K score excluding anti-dsDNA and complement items; 2) PGA-VAS <0.5; 3) Current prednisone dose <=5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE, were considered nonresponders.

At Week 52
Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Scale From Baseline to Weeks 24 and 52
Periodo de tiempo: Baseline, Weeks 24 and 52

The FACIT-F was a patient-completed questionnaire consisting of 13 items that assessed fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as: 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Adjusted mean values have been reported. The analysis was performed using analysis of covariance (ANCOVA) model.

Baseline, Weeks 24 and 52
Change in 36-Item Short Form Survey, Version 2 (SF-36 V2) Bodily Pain Domain Scale From Baseline to Weeks 24 and 52
Periodo de tiempo: Baseline, Weeks 24 and 52

The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.

Baseline, Weeks 24 and 52
Change in SF-36 V2 Physical Component Summary Scale From Baseline to Weeks 24 and 52
Periodo de tiempo: Baseline, Weeks 24 and 52

The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and the MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.

Baseline, Weeks 24 and 52
Change in Active Joint Count From Baseline to Weeks 24 and 52
Periodo de tiempo: Baseline, Weeks 24 and 52

Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Data after the first occurrence of intercurrent event (ICE), including major concomitant therapy violation, treatment failure requiring rescue medication or early discontinuation from the blinded period due to AE, death and lack of efficacy, was imputed using the worst post-baseline value from the following assessments: the last value available prior to the occurrence of the first ICE; all values available after the occurrence of the ICE. Participants with treatment discontinuation without any ICE above were evaluated under the treatment policy strategy. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.

Baseline, Weeks 24 and 52
Percentage of Participants Who Achieved a >=50% Reduction in Active Joint Counts at Each Study Visit, Among Participants With >=4 Active Joints at Baseline
Periodo de tiempo: At Weeks 24, 28, 32, 36, 40, 44, 48 and 52

Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders.

At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
Percentage of Participants Who Achieved a >=50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI) Total Activity Score at Each Study Visit
Periodo de tiempo: At Weeks 24, 28, 32, 36, 40, 44, 48 and 52

CLASI is a validated instrument for assessing cutaneous lupus erythematosus activity. It reports two global scores: one for current inflammatory activity (Total Activity Score), and one for damage (Total Damage Score). To calculate the total scores, trained assessors evaluate erythema, scale/hypertrophy, dyspigmentation, and scarring/atrophy/panniculitis at 13 anatomic locations plus additional assessments for mucosal lesions and alopecia. CLASI total activity score ranges from 0 to 70, with higher scores indicating increased disease severity. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders.

At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
Percentage of Participants Who Achieved Sustained OCS (<=5 mg/Day) From Week 40 Through Week 52
Periodo de tiempo: From Week 40 through Week 52

Sustained OCS was defined as all of the following: 1) No treatment with prednisone >5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders.

From Week 40 through Week 52
Cumulative Corticosteroid Use Through Week 52
Periodo de tiempo: Up to Week 52

Cumulative oral corticosteroid was represented in prednisone or equivalent only. The mean of the standardized area under the curve (AUC) through Week 52 have been reported. AUC was derived based on the actual dose participants have received. Standardized AUC was derived using AUC divided by days in study multiplied by 365.25 days for each participant.

Up to Week 52
Annualized Flare Rate Through Week 52
Periodo de tiempo: Up to Week 52

BILAG flare was defined as the occurrence of >=1 new BILAG A or >=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). The number of flares over the 52-week blinded treatment period has been reported. The number is calculating rate, which is the number of events (flares) over total participant-years (time period).

Up to Week 52
Number of Participants With Adverse Events (AEs)
Periodo de tiempo: Up to Week 52

An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.

Up to Week 52
Number of Participants With Adverse Events of Special Interests (AESIs), Including Infusion-related Reactions (IRRs), Neutropenia, Infections, and Thrombocytopenia
Periodo de tiempo: Up to Week 52

AESIs for this study were as follows: cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice; suspected transmission of an infectious agent by a study treatment (Hy's Law); IRRs (systemic IRRs only); grade >=3 infections; any hepatitis B reactivation; progressive multifocal leukoencephalopathy (PML); study drug-related neutropenia; study drug-related thrombocytopenia; gastrointestinal (GI) perforations; worsening of preexisting cardiac conditions.

Up to Week 52
Maximum Serum Concentration (Cmax) of Obinutuzumab
Periodo de tiempo: From Weeks 0-24 and Weeks 24-52

Cmax is defined as the maximum concentration of a drug in the serum. Cmax is reported at steady state. Hence, only one value for the specified assessment periods is reported here.

From Weeks 0-24 and Weeks 24-52
Trough Concentration (Ctrough) of Obinutuzumab
Periodo de tiempo: From Weeks 0-24 and Weeks 24-52

Ctrough is defined as the concentration immediately prior to the next dose at steady state (end of the dosing interval). Data were collected when the participant attended the next dose administration visits over the two time intervals.

From Weeks 0-24 and Weeks 24-52
Area Under the Concentration-time Curve (AUC) of Obinutuzumab
Periodo de tiempo: Week 0-52

AUC is defined as the area under the drug concentration-time curve and represents drug exposure over a specified time interval. Data presented here give exposure over the duration of 0 to 52 weeks.

Week 0-52
Number of Participants With Anti-drug Antibodies (ADAs) to Obinutuzumab
Periodo de tiempo: Up to Week 52

Participants who received obinutuzumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following obinutuzumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.

Up to Week 52

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Clinical Trials, Hoffmann-La Roche

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

26 de octubre de 2021

Finalización primaria (Actual)

15 de septiembre de 2025

Finalización del estudio (Estimado)

13 de marzo de 2028

Fechas de registro del estudio

Enviado por primera vez

7 de julio de 2021

Primero enviado que cumplió con los criterios de control de calidad

7 de julio de 2021

Publicado por primera vez (Actual)

15 de julio de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CA42750
  • 2020-005760-57 (Número EudraCT)
  • 2023-504774-38-00 (Otro identificador: EU CT Number)
  • 2023 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .